Onasemnogene Abeparvovec-brve
Phase 3
NovartisOnasemnogene Abeparvovec-brve is one of 13 therapeutic programs targeting Spinal Muscular Atrophy. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
14 competitors in Spinal Muscular Atrophy
#DrugCompanyPhaseTrials
1Spinraza
BiogenApproved
Evrysdi
RocheApproved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Amondys 45
Sarepta TherapeuticsApproved
Onasemnogene Abeparvovec
NovartisPhase 3
Salanersen
BiogenPhase 3
Apitegromab
SScholar Rock, Inc.
Phase 3
Taldefgrobep Alfa
BBiohaven Therapeutics Ltd.
Phase 3
Vesemnogene Lantuparvovec
LLantu Biopharma
Phase 3
Onasemnogene Abeparvovec-brve
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Spinal Muscular Atrophy1 trial
Sources
References
- [1]
- [2]
- [3]